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Abstract: (1) Background: This project evaluates the outcomes of a novel pharmacy-led model of
deprescribing unnecessary medications for care home patients. A feasibility study was conducted
in 2015 to explore exposure to inappropriate polypharmacy in patients residing in care homes
over a one-year timescale. The aim of this study was to present the results of this ongoing service
evaluation over a five-year period. (2) Methods: Data collection and risk assessment tools developed
during the feasibility study were used to measure the prevalence, nature, and impact of deprescribing
interventions by primary care pharmacists over a five-year period. A random sample of approximately
5% of safety interventions were screened twice yearly by the pharmacist leads as part of standard
practice. (3) Results: Over a period of five years there were 23,955 interventions (mean 2.3 per
patient) reported from the 10,405 patient reviews undertaken. Deprescribing accounted for 53% of
total estimated financial drug savings, equating to £431,493; and 16.1% of all interventions were
related to safety. (4) Conclusions: Medication reviews in care homes, undertaken by primary care
pharmacists who are linked to GP practices, generate a wide range of interventions commonly
involving deprescribing, which contributes significantly to the continuous optimisation of the
prescribing and monitoring of medicines.
Keywords: care homes; deprescribing; pharmacists
1. Introduction
1.1. Overview
Appropriateness, safety, and quality of prescribing are concepts closely linked to the overall
well-being of the frail, elderly patients living in care homes who often take multiple medicines and
have complex needs [1]. This study focuses on a model of medication optimisation reviews undertaken
by primary care pharmacists working with General Practitioners (GPs) in Somerset, which led to a
range of clinical recommendations in relation to drug prescribing and monitoring. This paper presents
the findings of the research specifically related to deprescribing. The following sections provide further
details on the background and considerations which led to selecting the aim of the present study.
1.2. Prescribing and Polypharmacy
Prescribing of medicines to patients is recognised as the most common healthcare intervention
in the National Health System (NHS), representing its highest expenditure (£8.8 billion in 2018)
immediately after staffing costs [2,3]. The vast majority of NHS prescription items are issued by GPs in
primary care. In England, there has been an increasing trend in prescribing [3] driven by a combination
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of numerous factors. These include population growth, higher proportion of the older population,
increase in diagnosis capability, and availability of new medicines to prevent or reduce the risk of
potential health problems. These factors have also contributed to the rise of a phenomenon defined in
clinical practice and known as polypharmacy, particularly occurring in debilitated populations such
as the frail elderly and those with co-morbidities, whereby patients receive a combination of several
medicines. These are common features of a significant proportion of patients residing in nursing and
residential homes [4].
Taking multiple medicines is deemed beneficial if patients are adherent to this approach, tolerate
such combinations well, and the therapy is appropriate to treat their medical conditions, with the
ultimate goal of maintaining or improving quality of life. However, polypharmacy is considered
inappropriate if the medication is clinically unnecessary, in cases where patients do not benefit from
the prescribed therapy as intended, or the risks of harm from taking combined medicines are higher
than the potential benefits; it can lead to intolerable side-effects, difficulty in taking medication, and
adverse interactions between drugs [5].
1.3. Medicines Optimisation and Deprescribing
Deprescribing has been the subject of growing interest in the scientific research community
in recent years [6–12]. Deprescribing is a complex process required for the safe and effective
cessation (withdrawal) of inappropriate medication. It considers the patient’s physical functioning,
co-morbidities, preferences, and lifestyle. Despite limited established guidance and evidence
surrounding its principles and outcomes, the emerging research suggests that appropriate deprescribing,
especially for older patients with complex regimens, is generally safe, and patients are receptive to
it [13–19].
A systematic review in 2008 [20] investigated clinical trials undertaken since 1966 which included
withdrawal of specific classes of medicines in patients aged 65 years and over. The authors found
31 relevant studies with almost 9000 patients and showed evidence of benefits and safety in the
short-term of stopping psychotropics, antihypertensives, and benzodiazepines. Another systematic
review [21], published in 2014, found an association between deprescribing and improvement of
clinical management of falls and cognitive function, which are recognised as significant morbidity and
mortality factors. A more recent systematic review [22] of deprescribing interventions in hospitalised
patients found that stopping inappropriate medications is feasible, effective, and safe. However, to
date there have been no systematic reviews of the literature of deprescribing in care home settings.
1.4. Medicines Interventions in Care Homes
The “Care homes’ use of medicines study (CHUMS)” [23] highlighted the need for and the benefits
of pharmacists’ interventions in patient care, medicines optimisation, and safety. It found that the 256
participants from 55 care homes were on average prescribed 7.2 medicines each. It also estimated
that on any given day 70% of patients were subject to at least one medication error associated with an
adverse event caused by poor clinical management such as monitoring (14.7%), dispensing (9.8%),
administration (8.4%), and prescribing (8.3%). The authors concluded that care home patients were
exposed to an unacceptable level of medication related errors. This paper called for action from all
involved and has also influenced subsequent national guidance in the United Kingdom (UK).
A recent cohort study [24] concluded that polypharmacy is common in nursing home residents in
Europe and decisions to deprescribe are dependent on individual and organisational factors such as
clinical conditions and staff involved.
1.5. Study Setting
The most significant structural reform in recent years in the NHS in England was the establishment
of Clinical Commissioning Groups (CCGs) in April 2013. Each one of these clinically-led organisations
is representative of all GPs in a given geographical area. CCGs have the responsibility of contracting
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most community and hospital health care services, including prescribing for local patients on behalf of
and overseen by NHS England (NHSE). The NHS Somerset CCG Medicines Management Team has
historically and to varying degrees facilitated medicines optimisation reviews for patients living in
care homes, as a way to reach out to patients who are predominantly frail, elderly, and living with
co-morbidities, as well as providing support for carers. In Somerset, in 2014, a novel model was
developed in order to standardise medication optimisation reviews to patients in care homes. At the
time there was emerging evidence indicating that there was a growing need for establishing this type
of service.
As part of this model of care, a team of primary care pharmacists, funded by NHS Somerset
CCG supported GP practices in undertaking medication optimisation reviews in care homes. The aim
of the service was to address inappropriate polypharmacy and prevent drug-related harm, utilising
primary care pharmacists in liaison with GPs. A feasibility study was conducted in 2015 to evaluate a
number of aspects surrounding this model of deprescribing of medicines in a sample of care homes
in Somerset [25]. As a result, the Clinical Operations Group at NHS Somerset CCG recognised the
benefits to patients and the local healthcare system by agreeing to grant recurrent and ongoing funding
for this novel model of care. Likewise, nationwide investment in the form of support to care homes was
recently launched by NHSE as “Medicines Optimisation in Care Homes (MOCH)” with the purpose of
improving the safety and quality of care for people in care homes [26]. The MOCH service is currently
commissioned through NHS Somerset CCG to local secondary care providers, and is based on the
original Somerset model of care; funding is expected to be transferred to the emerging Primary Care
Networks [27].
This project evaluates the outcomes of this novel pharmacy-led model of deprescribing of
unnecessary medications for care home patients. The 2015 feasibility study to explore exposure
to inappropriate polypharmacy in patients residing in care homes was conducted over a one-year
timescale [25]. The purpose of this paper is to present the results of this ongoing service evaluation
over a five-year period.
1.6. Aim
The aim of this research was to evaluate the prevalence and nature of interventions, the rationale
for stopping medicines, and the impact of deprescribing on patient safety in care homes over a
five-year period.
2. Materials and Methods
2.1. Overview of Study
The study adopted a mixture of quantitative and qualitative methodology in order to address
the aims of the study. Data collection and risk assessment tools were developed during a feasibility
study undertaken in 2015 [25]. These were used to measure the prevalence, nature and impact of
deprescribing interventions by primary care pharmacists over a five-year period. The number of
deprescribing interventions that occurred were quantified within eight distinct categories, and the
financial costs were calculated over a period of five years. A safety risk assessment took place for all
interventions, and further case studies were described to illustrate the nature of these.
2.2. Approvals and Ethical Considerations
Under the NHS Healthcare Research Authority [28] standards and definition of research, the
feasibility project from which this present study builds upon, was formally classified as a service
evaluation and therefore did not require submission to the NHS Research and Development or ethical
review by a NHS Research Ethics Committee.
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2.3. Model of Service Delivery
The service was designed by two of the authors (A.A. and S.G.) in order to develop a standardised
and consistent approach across the county of Somerset. The model of service delivery was based on the
skill set of the existing pharmacy staff at the time, in addition to critical incidents and feedback from a
variety of stakeholders (care homes’ staff, GP practices, and primary care pharmacists). Considering
Somerset’s wide rural geography, the aim of the programme was to offer at least one medicines
optimisation visit to as many care homes (residential, nursing and mixed) as possible, by primary care
pharmacists on behalf of GP practices.
The time and level of support allocated for the service was agreed upon with the respective CCG
Locality Pharmacist Manager and influenced by a number of factors such as engagement from GP
practices; primary care pharmacists’ availability; skills and confidence; number of care home patients
registered with each GP practice; and geographic area covered by the prescribing support pharmacists.
The type of service provided was to some extent dependent on the degree of involvement from other
healthcare professionals, such as whether a GP visited the care home alongside the pharmacist, or if
pharmacists undertook the review and had a prior discussion with the prescriber at the GP practice.
Quality Assurance
The CCG Locality Medicines Managers reviewed all patient-anonymized care home reports
submitted by the primary care pharmacists; and twice yearly the CCG pharmacist project lead (A.A.)
undertook a review of a sample of approximately 5% of safety interventions with the team colleague
who leads on safety. This is standard practice and considered to be an effective mechanism of providing
feedback to the team. Good practice, learnings and relevant observations are widely shared with the
primary care community through regular email updates, Learning Engagement Network meetings,
and GP Prescribing Leads events.
2.4. Data Collection Tools
Standardised data collection tools used by the pharmacists were developed as part of the feasibility
study conducted in 2015 [25]. The primary care pharmacists continued to use these forms for 2015–16,
2016–17, 2017–18, and 2018–19 as part of care home visits, which the CCG used to collate overall
information on interventions. These consisted of the following:
- Form 1: Care Home Data Collection Form (Table S1),
- Form 2: Care Home Intervention Codes (Table S2),
- Form 3: Care Home Safety Risk Assessment Scoring (Table S3), and
- Form 4: Care Home Visit Flowchart (Figure S1).
Forms 1,2, and 4 were developed in conjunction with the pharmacy team which involved several
iterations to produce the most effective version to capture the interventions in an efficient manner.
Development of Safety Risk Assessment Scoring Scale
The safety risk assessment scoring scale (Form 3) was developed locally [25] based on the findings
from well recognised studies [29,30] and utilised consensus methodology. The first phase of the process
consisted of a peer-consensus from two CCG lead pharmacists. Phase 2 involved a clinical validation
panel (two GPs, one hospital and one integrated-services pharmacist), and the third phase comprised
expert review by one care of the elderly consultant [25]. A number of changes were made to the scale
between each phase until 100% agreement was reached from all parties.
2.5. Study Procedures
All intervention data were captured on Form 1 by the pharmacist conducting the intervention,
using Forms 2 and 3 to code the data. Likewise, the pharmacists also calculated the estimate drug
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saving by referring to the most recent edition of the Drug Tariff to find the price of the drug. All
forms were anonymised before being sent from the care home. Completed Forms 1 were received
electronically by the CCG Medicines Management team, and the administrator merged the information
with an overall data Excel spreadsheet (Microsoft Office 2010 version 16.0) populated with a macro.
2.6. Analysis
The data were extracted from the Excel spreadsheet containing information from each financial
year and overall five years. The quantitative information included the number of care homes reviewed,
number of patient reviews, time spent on review, number of interventions and type, deprescribing
category, safety risk level, age of patient, total number of drugs, potential annual drug savings, and
savings from deprescribing. The 28-day cost of the drug was multiplied by thirteen to obtain an
annual estimation of the cost saving. Pharmacists’ time was estimated based on an hourly rate of £26.
Overall cost savings were calculated by subtracting the pharmacists’ time away from the overall drug
cost saving.
The descriptive data were extracted for individual patients to illustrate the nature of the
intervention, actions taken by the care home and/or GP practice, and outcomes from safety
interventions recorded.
3. Results
In the period between April 2018 and March 2019, of the 27 pharmacists commissioned by NHS
Somerset CCG, 25 conducted care home reviews which were included in the service Level Agreement
(between 4 and 12 h per week). In comparison, at the start of the model of delivery in 2014–15, 12
pharmacists provided this service.
As an example of one-year’s output, Table 1 summarises the results for 2018–19 across GP practices
grouped into seven geographical areas (known as GP Federations). There have been 2927 patient
reviews across 121 nursing and residential care homes of which 17 received a second visit. The overall
spend in pharmacist time was £63,444, equating to £21.68 per patient review.
Table 1. Overall summary data for care home visits in Somerset in 2018–19.
GP
Federation
Number of
Care Homes
Number of
Beds
Number of
Registered
Patients
Number of Care
Home Visits
Number of Patient
Reviews
Hours Spent on
Review
GP
Federation 1 19 580 442 8 106 65.95
GP
Federation 2 22 495 412
17 (1st visit) + 3
(2nd visit)
347 (1st visit) + 46
(2nd visit) 373.75
GP
Federation 3 36 1192 939
25 (1st visit) + 14
(2nd visit)
939 (1st visit) + 346
(2nd visit) 1016.45
GP
Federation 4 37 810 578 8 181 108.50
GP
Federation 5 38 1169 919 30 524 423.25
GP
Federation 6 60 1792 1363 27 457 344.25
GP
Federation 7 16 446 382 6 170 108.00
CCG Total 228 6484 5035 121 (1st visit) + 17(2nd visit) = 138
2535 (1st visit) + 392
(2nd visit) = 2927 2440.15
Table 2 presents the total type of interventions, as well as those coded as potentially having an
impact on patient safety, and the nature of deprescribing interventions. Data for the 2018–19 year
shows that a total of 5168 interventions were recorded for 2927 patient reviews, of which deprescribing
represents approximately one quarter. Although a small proportion, there were also 86 opportunities
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identified to initiate appropriate medication. The overall savings were £148,656 when subtracting the
cost associated with pharmacists’ time.
Table 2. Overall summary data for interventions care home visits in Somerset in 2018–19.
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identified as part of the reviews were deemed minor or moderate/significant (combined 98.7%). It was
expect d that these patients would have been likely to experience increased side-effects and need
a ditional monitoring had the pharmacists not intervened. Thirteen interventions were class
as major/serious, indicating that the probability of admission was high had these not occurred.
Moreover, for the first time since the start of the project, there were two interventions classed as
Catastrophic/Potentially Lethal, meaning that if the interventions had not taken place, hospital admission
would have been certain. On these two occasions the errors were linked to unintended prescribing
of a high-risk drug. In the first case a Direct Oral Anticoagulant (DOAC) was initiated for the
incorrect patient for whom there was no indication of such a drug. In the second case, the patient
had been admitted to hospital with hypoglycaemia but the dose of a sulphonylurea was doubled in
the care home instead of halved after discharge from hospital. Pharmacists reported that the most
common reason for deprescribing was that drugs were no longer required by the patients (59.3% of
deprescribing interventions).
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Table 3. NHS Somerset CCG examples of safety interventions review undertaken 03/01/2019.
Age of
Patient
(years)
Total Drugs on
Medication
Administration
Record
Drug/Product/
Appliance
Name
Care Home
Actions
Pharmacist/GP
Practice
Actions
Risk
Safety
Scoring
Comments &
Outcomes
from Safety
Interventions
Risk Safety
Scoring Review
by Lead
Pharmacists on
03/01/2019
94 10
On dual
antiplatelets—
discharge
letter from 18
February. Had
acute
myocardial
infarction—to
remain on
clopidogrel for
12 months
only
Not applicable
Amend
directions on
clopidogrel to
give a stop
date of
February 2019
1
94-year-old
with history of
falls could
have been on
dual
antiplatelets
indefinitely
1
102 12
Quinine
bisulphate for
leg
cramps—no
longer
recommended
interaction
with
furosemide +
low estimated
Glomerular
Filtration Rate
(eGFR)
Try without +
monitor
Move to
variable use
repeat +
reduce
quantity
1
Quinine can
be associated
with
thrombocytopenia
1
82 15
Discharged
from hospital
on quetiapine
but seen
21.3.18 by
Community
Mental Health
Team (CMHT)
and this was
stopped (still
on repeat)
Do not
administer
Discontinue
quetiapine 1
Meds not
aligned
following
CMHT review
2
89 9
On apixaban
2.5 mg twice
daily
(BD)—needs
weight to
determine if
dose is ok
Weight patient
Weight = 64.4
kg +
creatinine
<133. Needs 5
mg BD
2
Currently on
sub-therapeutic
dose of Direct
Oral
Anticoagulant
(DOAC)
2
96 9
Nitrofurantoin
50 mg tab 28
1on stopped.
GP stopped
and deemed
replacement
NOT required
and monitor
for symptoms
of urinary
tract infections
(UTIs)
Amend
records
Update
patient
medication
record (PMR)
3
Risk of
peripheral
neuropathy.
Antibacterial
efficacy
depends on
renal secretion
of drug into
urinary tract.
Avoid if eGFR
< 45
ml/min/1.73
m2 as long
term use.
eGFR at
review time 17.
Therefore, this
drug
inappropriate
and also
appeared on
Eclipse Red
Alerts.
3
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Table 3. Cont.
Age of
Patient
(years)
Total Drugs on
Medication
Administration
Record
Drug/Product/
Appliance
Name
Care Home
Actions
Pharmacist/GP
Practice
Actions
Risk
Safety
Scoring
Comments &
Outcomes
from Safety
Interventions
Risk Safety
Scoring Review
by Lead
Pharmacists on
03/01/2019
89 14
Apixaban 5
mg tabs—no
obvious
indication
tasked X as
concerned re
dose-lady is
<60 kg and
over 80 years
old.
GP error. This
medication
was not
indicated for
this lady and
the dose was
high for her
age and
weight.
GP informed
of error and
submitted
critical
incident form.
Further error
noticed
2/1/2019 as
apixaban
reissued after
GP had
stopped. Care
home had
reordered, and
prescription
clerk reissued -
prescription
stopped today
before it had
reached
patient.
Further
incident
added to
critical
incident at
surgery.
3
Apixaban
added to
wrong records
and
prescription
issued - given
to patient for
three months.
5 mg tablets
given and
patient over 80
years old and
<60 kg could
have been
serious if no
intervention.
Critical
incident error
reported by X
and Datix
report by Y
update 2/1/19
restarted by
GP 24/12/18
care home had
requested, and
untrained
person
reissued.
Stopped
prescription
before it got to
care home
2/1/19
4
(“Drug related
incident
prevented which
could have led to
long-term patient
harm or death of
patient”)
The lead pharmacist for the programme delivery (A.A.) and the colleague responsible for safety
across the organization (S.G.) carried out a joint review of a sample of safety interventions twice yearly.
The sample comprised the last 30 to 40 interventions collated from the last entries for the period being
reviewed until at least three examples of each risk level had been identified (all interventions scored
as level 4 are always independently reviewed by two people). An extract for the latest sample of
interventions reviewed is provided in Table 3:
Table 4 provides an overview of the progress over five years from baseline in 2014–15 up until
2018–19. This demonstrates that 10,405 patient reviews led to an average of 2.3 interventions per
patient and just over a sixth of all interventions were reported as having a potential impact on patient
safety (16.1%). Over time the estimated potential annual drug savings was approximately £812k with
savings per patient review gradually reduced from £89 to £78. Overall, the savings from deprescribing
over five years amounted to £431,483 (53% of total savings):
Figure 1 presents the number of safety interventions identified each year by the primary care
pharmacists. The main changes have been an increase in the overall number of minor safety interventions
reported, and a reduction in the proportion of those categorised as serious/moderate, with the only two
catastrophic/potentially lethal identified in 2018–19.
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Table 4. NHS Somerset CCG progress data summary of care homes reviews by financial year from
April 2014–15 to March 2019.
Financial
Year
Number of Care
Homes Visits
(% From Total)
Number of
Patient
Reviews
Total Number of
Interventions
(Number Per
Patient Review)
Potential Annual
Drugs Savings
(Saving Per Patient
Review)
Deprescribing
(% From Total
Savings)
Total safety
Interventions
(% From All
Interventions)
2014–15
64
1195
2817 £106,762 £61,180
(27) (2.3) (£89) (57)
2015–16
62
1222
3631 £101,083 £62,117 660
(27) (3.0) (£83) (61) (16.5)
2016–17
84
1622
4654 £122,479 £73,205 888
(35) (2.7) (£75) (60) (19.1)
2017–18
151
3439
7685 £269,512 £125,149 1178
(64) (2.2) (£78) (46) (15.3)
2018–19
138
2927
5168 £212,100 £109,842 1143
(61) (1.8) (£72) (52) (22.1)
Total for
5-year
period
499 10,405 23,955(2.3) £812,441(£78)
£431,493
(53)
3869
(16.1)
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4. Discussion
The aim of this study was to explore the impact of deprescribing interventions over a five-year
period. In summary, there were nearly 24,000 interventions reported across the 25 pharmacists
delivering the scheme, who undertook over 10,000 patient reviews. This equated to an average of over
two interventions per patient. Deprescribing accounted for over half of the total estimated financial
drug savings, equating to nearly half a million pounds. Approximately one-sixth of all interventions
were related to safety.
These findings suggest that the Somerset model of pharmacist deprescribing in care homes has an
important impact on patient care in terms of increasing appropriate prescribing, enhancing safety and
producing significant cost savings for the NHS. The data generated since the feasibility study [25] was
conducted demonstrate that deprescribing interventions by pharmacists in care homes provided a
consistent and sustainable approach over 5 years.
Pharmacy 2019, 7, 105 10 of 13
Since the service was first initiated in 2014, the NHS Somerset CCG programme has expanded
considerably and in recent years pharmacists reached out to more than twice the number of patients
and care homes when compared to the start of the scheme. Medicines optimisation in care homes have
become embedded in the NHS Somerset CCG medicines management workplan and part of the core
prescribing support service to GP practices. The results gathered show that the main opportunities
were in deprescribing unnecessary medicines and medication safety; pertinently, both themes are
under close national attention as part of the national health and care agenda. Whilst contributing to
the safety agenda, deprescribing also consistently remained the most significant intervention in terms
of releasing significant estimated financial savings for an increasingly constrained healthcare budget.
Over the period of five years, it equated to over £431k (53%) from a total savings of £812,441.
The evidence base surrounding deprescribing continues to grow, and despite the lack of systematic
reviews specifically concerning the care homes setting, a recent randomised controlled trial [29] in
59 Dutch nursing homes demonstrated that deprescribing can be effectively and safely achieved in a
significant proportion of residents (29.5% to 39.1%). A Cochrane review updated in 2016 [30] despite
being inconclusive on the impact on clinical and safety aspects from medication optimisation in care
homes, highlights that evidence was found in relation to solving medication problems.
In this study, sub-analysis of the most recent financial year (2018–19) revealed that most
deprescribing interventions as part of 138 care home visits were due to the lack of a need for
medicines (59.3%), contributing to a reduction in unnecessary polypharmacy. These findings resonate
with a recent systematic review and meta-analysis by Hansen et al. [31]. The research concluded
that deprescribing can be successfully achieved in association with behaviour change techniques,
resulting in a decrease in medications and inappropriate prescribing in older people. A limitation of
this research lies in the fact that formal and systematic economic analysis has not been performed as
part of this evaluation; nevertheless, available data shows that it delivers potential considerable drug
savings, with a 2.34 times equivalent return on investment in pharmacist salary time in 2018–19. This
is without factoring in the potential improved outcomes and reduced NHS and social care activity
from the scheme. Another limitation remains in the tool adapted from the Medicines Management
team from the Enhancing Quality of Life in Patients (EQUIP) and Discharge Medication Review
(DMR) studies [32,33], which was not fully validated and therefore it is unclear whether it can be
adequately and accurately applied to all types of interventions. However, findings from the feasibility
study [25] were still observed in that reducing the burden of polypharmacy for patients in care homes
remained an important aspect of effective prescribing support provided by primary care pharmacists,
and contributed to a patient-centred approach to their safety and care.
Nonetheless, the resources developed to record and analyse data from medication reviews in
care homes have already been shared with neighbouring CCGs and through the national Future
Learn platform [34] dedicated section for the NHS England MOCH programme. With the imminent
formation of Primary Care Networks [35] it is hoped that a structured programme will be developed
for primary care clinical pharmacists to routinely undertake medication reviews for care home patients.
It is recommended that consideration is given from this five-year evaluation which signals that a
centralised model of management covering the whole county has been instrumental in providing a
structured approach, as well as facilitating a platform for skill development and sharing of best practice.
5. Conclusions
Medication reviews in care homes, undertaken by primary care pharmacists who are linked to
GP practices, generate a wide range of interventions commonly involving deprescribing. This service
contributes significantly to the continuous optimisation of prescribing and monitoring of medicines.
Medication optimisation reviews in residential and nursing homes therefore remain in the Medicines
Management Team core agenda due to its established contribution to patient safety and impact on
cost-effective prescribing over five years. In conclusion, the present research highlights that the work
undertaken by primary case pharmacists and the use of standardied tools in Somerset for coding
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interventions and attributing safety scores are invaluable to collecting important data, and to build a
clearer picture of deprescribing in the context of service cost-effectiveness.
Supplementary Materials: The following are available online at http://www.mdpi.com/2226-4787/7/3/105/s1,
Figure S1: Care Home Visit Flowchart, Table S1: Care Home Data Collection Form, Table S2: Care Home
Intervention Codes, Table S3: Care Home Safety Risk Assessment Scoring.
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